Deal-Making

Danish pharma giant Novo Nordisk will acquire Novavax’s manufacturing facility in the Czech Republic.

Deal-Making

KBI will use its monoclonal antibody (mAb) platform to produce ATI’s lead candidate for clinical testing.

Facilities & Capacity

The five Chinese companies targeted by the US government’s BIOSECURE Act receive a proverbial stay of execution.

Facilities & Capacity

“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.

Global Markets

The five Chinese companies targeted by the US government’s BIOSECURE Act receive a proverbial stay of execution.

Therapeutic Class

Fostering a culture of compliance and quality alignment with Western regulators is vital for India's biomanufacturing growth: “If you are open for business every day, you have to be ready for inspection every day.”

Regulations

Pfizer, Merck & Co., and Moderna remain upbeat over future dealings with the US government despite President-elect Trump telling vaccine-sceptic and alternative-medicine proponents to “go wild on health.”

Facilities & Capacity

While much talk at CPHI Milan centered on the potential impact of BIOSECURE, other US policies – particularly the Inflation Reduction Act (IRA) – are proving a boon for Indian CDMOs.

Therapeutic Class

“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.

Upstream & Downstream Processing

“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.

Upstream & Downstream Processing

“Biotech funding is improving. It's not robust, but it's improving,” says Thermo Fisher’s CEO amid numerous reasons to be cheerful in an ever-changing world.